MCID: CRV040
MIFTS: 54

Cervix Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervix Carcinoma

MalaCards integrated aliases for Cervix Carcinoma:

Name: Cervix Carcinoma 12 15 74
Carcinoma of Cervix 12 30 6
Carcinoma of the Cervix Uteri 12
Carcinoma Cervix Uteri 12
Cancer of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2893
NCIt 51 C9039
SNOMED-CT 69 93752005
UMLS 74 C0302592

Summaries for Cervix Carcinoma

Disease Ontology : 12 A cervical cancer that is located in the cervix uteri or located in the cervical area and that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Cervix Carcinoma, also known as carcinoma of cervix, is related to cervix uteri carcinoma in situ and cervix small cell carcinoma. An important gene associated with Cervix Carcinoma is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are MAPK signaling pathway and DNA Damage. The drugs Aluminum hydroxide and Bethanechol have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and lymph node, and related phenotypes are homeostasis/metabolism and hematopoietic system

Related Diseases for Cervix Carcinoma

Diseases related to Cervix Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 cervix uteri carcinoma in situ 32.2 CDKN2A INSM1 TP53
2 cervix small cell carcinoma 32.1 CDKN2A MAPK8IP1 MAPK8IP2 TP53
3 suppressor of tumorigenicity 3 31.9 CDKN2A FHIT TP53
4 endocervical carcinoma 31.8 CDKN2A MAPK8IP1
5 cervical cancer 31.5 CDKN2A FGFR3 FHIT HOXA11-AS STAT3 TP53
6 keratinizing squamous cell carcinoma 30.0 CDKN2A TP53
7 transitional cell carcinoma 29.7 CDKN2A FGFR3 TP53
8 papilloma 29.6 CDKN2A FGFR3 TP53
9 breast cancer 28.5 ABCB1 ABCC1 CDC27 CDKN3 FHIT HOXA11-AS
10 high-grade neuroendocrine carcinoma of the cervix uteri 12.5
11 glassy cell carcinoma of the cervix uteri 12.4
12 adenoid basal carcinoma of the cervix uteri 12.4
13 papillary carcinoma of the cervix uteri 12.4
14 cervical clear cell adenocarcinoma 11.4
15 cervical endometrioid adenocarcinoma 11.4
16 primitive neuroectodermal tumor of the cervix uteri 11.2
17 cervical adenosquamous carcinoma 11.1
18 cervical squamous cell carcinoma 11.1
19 exocervical carcinoma 11.1
20 cervical adenocarcinoma 11.1
21 cervical adenoid cystic carcinoma 11.1
22 cervical adenoid basal carcinoma 11.1
23 cervical large cell neuroendocrine carcinoma 11.1
24 non-invasive bladder papillary urothelial neoplasm 10.4 FGFR3 TP53
25 bladder papillary transitional cell neoplasm 10.3 FGFR3 TP53
26 ophthalmia neonatorum 10.3 MAPK8IP1 STYK1
27 urinary tract papillary transitional cell benign neoplasm 10.3 FGFR3 TP53
28 microsporidiosis 10.3 ABCB1 ABCC1
29 in situ carcinoma 10.3
30 bladder squamous cell carcinoma 10.3 CDKN2A TP53
31 colchicine resistance 10.2 ABCB1 ABCC1
32 spitz nevus 10.2 CDKN2A TP53
33 skin carcinoma in situ 10.2 CDKN2A STAT3
34 aging 10.2 FOXO3 STAT3 TP53
35 bladder carcinoma in situ 10.2 CDKN2A TP53
36 megaesophagus 10.2 CDKN2A FHIT TP53
37 gastric adenosquamous carcinoma 10.2 CDKN2A STAT3 TP53
38 barrett's adenocarcinoma 10.2 CDKN2A FHIT TP53
39 supratentorial cancer 10.2 CDKN2A STAT3 TP53
40 vulva squamous cell carcinoma 10.2 CDKN2A TP53
41 bone squamous cell carcinoma 10.2 CDKN2A STAT3
42 cerebrum cancer 10.2 CDKN2A STAT3 TP53
43 central nervous system cancer 10.2 CDKN2A STAT3 TP53
44 retinal cancer 10.2 CDKN2A CDKN3 TP53
45 ocular cancer 10.2 CDKN2A CDKN3 TP53
46 scrotal carcinoma 10.1 CDKN2A TP53
47 respiratory system cancer 10.1 CDKN2A STAT3 TP53
48 gastrointestinal system cancer 10.1 CDKN2A STAT3 TP53
49 endocrine gland cancer 10.1 CDKN2A STAT3 TP53
50 larynx cancer 10.1 CDKN2A FHIT TP53

Graphical network of the top 20 diseases related to Cervix Carcinoma:



Diseases related to Cervix Carcinoma

Symptoms & Phenotypes for Cervix Carcinoma

MGI Mouse Phenotypes related to Cervix Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ABCB1 ABCC1 CDKN2A DUSP3 FGFR3 FHIT
2 hematopoietic system MP:0005397 10.07 ABCB1 ABCC1 CDKN2A DUSP3 FGFR3 FHIT
3 endocrine/exocrine gland MP:0005379 10.06 ABCB1 CDKN2A FOXO3 INSM1 MAPK8IP1 MAPK8IP2
4 digestive/alimentary MP:0005381 10.03 ABCB1 CDKN2A FGFR3 FHIT FOXO3 INSM1
5 mortality/aging MP:0010768 10.03 ABCB1 ABCC1 CDKN2A FGFR3 FHIT FOXO3
6 neoplasm MP:0002006 9.7 CDKN2A FGFR3 FHIT FOXO3 NBN STAT3
7 nervous system MP:0003631 9.7 ABCB1 ABCC1 CDKN2A FGFR3 FOXO3 INSM1
8 reproductive system MP:0005389 9.28 ABCB1 CDKN2A FGFR3 FOXO3 MAPK8IP1 MAPK8IP2

Drugs & Therapeutics for Cervix Carcinoma

Drugs for Cervix Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
2
Bethanechol Approved Phase 4 674-38-4 2370
3
Peppermint Approved Phase 4
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
6
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
7
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
8
Meperidine Approved Phase 4 57-42-1 4058
9
Polihexanide Approved, Investigational Phase 4 28757-47-3
10
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
11
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
12
Nicotine Approved Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 54-11-5 89594 942
13
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
14
Nevirapine Approved Phase 4 129618-40-2 4463
15
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
16
Ferrous fumarate Approved Phase 4 141-01-5
17
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
18
Vitamin C Approved, Nutraceutical Phase 4,Phase 2 50-81-7 54670067 5785
19 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
20 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Monophosphoryl lipid A Phase 4
22 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Muscarinic Agonists Phase 4
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Cholinergic Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
27 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Epoetin alfa Phase 4,Phase 3 113427-24-0
31 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
32 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
33 Narcotics Phase 4,Phase 3,Not Applicable,Early Phase 1
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Adjuvants, Anesthesia Phase 4,Phase 3,Not Applicable
36 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
37 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
38 Anesthetics, General Phase 4,Phase 3,Not Applicable
39 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
40 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Psychotropic Drugs Phase 4,Phase 3,Phase 2
43 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
44
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
45 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
46 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
47 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
50 Fluorodeoxyglucose F18 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1400)
# Name Status NCT ID Phase Drugs
1 FASTER-Tlalpan Study Unknown status NCT03105856 Phase 4
2 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Unknown status NCT02629510 Phase 4 Tachosil
3 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
4 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
5 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
6 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
7 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Unknown status NCT01031069 Phase 4
8 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
9 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
10 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
11 Effect of HPV Vaccination on Women Aged 25 Years Completed NCT02296255 Phase 4
12 Comparing Health Services Interventions for the Prevention of HPV-related Cancer Completed NCT02837926 Phase 4
13 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
14 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
15 Application of Tachosil During Lymphadenectomy Completed NCT03752606 Phase 4
16 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
17 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects Completed NCT00947115 Phase 4
18 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
19 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
20 Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy Completed NCT02684942 Phase 4 Meperidine;Fentanyl
21 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
22 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
23 Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection Completed NCT01571141 Phase 4
24 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
25 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
26 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
27 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
28 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
29 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Recruiting NCT03423082 Phase 4 18F fluciclovine
30 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
31 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
32 Postpartum HPV Vaccination Recruiting NCT03451071 Phase 4 Gardasil9
33 CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening (CITRUS Study) Active, not recruiting NCT01895517 Phase 4
34 Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
35 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
36 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
37 The KEN SHE Study on HPV-vaccine Efficacy Enrolling by invitation NCT03675256 Phase 4
38 To Evaluate the Efficacy and Safety of PEG-rhG-CSF(Jinyouli®) in Reducing Neutropenia in Patients With Cervical Cancer Not yet recruiting NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
39 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
40 A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
41 Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis Unknown status NCT00846508 Phase 3 Cisplatin
42 Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer Unknown status NCT00548821 Phase 3 Cisplatin
43 Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer Unknown status NCT02446652 Phase 3 Hydralazine/Magnesium;Placebo;Carboplatin;Paclitaxel
44 Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
45 Adjuvant Chemotherapy for Locally Advanced Cervical Cancer Unknown status NCT02036164 Phase 3 Cisplatin;Paclitaxel;Carboplatin
46 Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
47 Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
48 Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer Unknown status NCT01999933 Phase 2, Phase 3 cisplatin(DDP) weekly;docetaxel plus cisplatin;docetaxel plus cisplatin
49 Usefulness of FDG-PET for Advanced Cervical Cancer Unknown status NCT00146458 Phase 3
50 Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients Unknown status NCT01000415 Phase 3

Search NIH Clinical Center for Cervix Carcinoma

Genetic Tests for Cervix Carcinoma

Genetic tests related to Cervix Carcinoma:

# Genetic test Affiliating Genes
1 Carcinoma of Cervix 30 FGFR3

Anatomical Context for Cervix Carcinoma

MalaCards organs/tissues related to Cervix Carcinoma:

42
Cervix, Testes, Lymph Node, Breast, Lung, T Cells, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Carcinoma:

20
The Cervix Uteri Or

Publications for Cervix Carcinoma

Articles related to Cervix Carcinoma:

(show top 50) (show all 409)
# Title Authors Year
1
Treatment of cervix carcinoma FIGO IIIb with Photofrin II as a radiosensitizer: a case report. ( 30892313 )
2019
2
Small cell carcinoma of cervix: A population-based study evaluating standardized provincial treatment protocols. ( 30723760 )
2019
3
Increasing aggressiveness of patient-derived xenograft models of cervix carcinoma during serial transplantation. ( 29765518 )
2018
4
Tanshinone IIA inhibits cervix carcinoma stem cells migration and invasion via inhibiting YAP transcriptional activity. ( 29909343 )
2018
5
Squamous cell carcinoma of cervix origin with rare metastasis to the colon. ( 30264019 )
2018
6
Comparative Evaluation of a 6MV Flattened Beam and a Flattening Filter Free Beam for Carcinoma of Cervix – IMRT Planning Study ( 29580032 )
2018
7
Image-Guided High-Dose Rate Brachytherapy in Cervix Carcinoma Using Balloon Catheter and Belt Immobilization System. ( 26868850 )
2017
8
Dosimetric influence of filtered and flattening filter free photon beam on rapid arc (RA) radiotherapy planning in case of cervix carcinoma. ( 27790073 )
2017
9
Extra-peritoneal laparoscopic para-aortic lymphadenectomy for staging of uterine cervix carcinoma. ( 28153518 )
2017
10
The induction of oxidative stress in cervix carcinoma cells by levoglucosenone derived 4-S-salicyl derivative and (1-4)-S-thio-disaccharides. Part 4. ( 28185719 )
2017
11
Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma. ( 28359677 )
2017
12
DCE-MRI of patient-derived xenograft models of uterine cervix carcinoma: associations with parameters of the tumor microenvironment. ( 29100521 )
2017
13
Lymphoepithelioma-like carcinoma of cervix: Cytological Features on Conventional Cervical Smear. ( 28211234 )
2017
14
Squamous Cell Carcinoma of Cervix with Isolated Metastasis to Ethmoidal Sinus: A Rare Occurrence. ( 28658774 )
2017
15
Association of Neo Angiogenesis by CD34 Expression and Clinicopathologic Features in Squamous Cell Carcinoma of Cervix. ( 28724267 )
2017
16
STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. ( 26563366 )
2016
17
Modulation of RhoA GTPase Activity Sensitizes Human Cervix Carcinoma Cells to γ-Radiation by Attenuating DNA Repair Pathways. ( 26649141 )
2016
18
Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. ( 27368915 )
2016
19
RGDS- and TAT-Conjugated Upconversion of NaYF4:Yb(3+)/Er(3+)&SiO2 Nanoparticles: In Vitro Human Epithelioid Cervix Carcinoma Cellular Uptake, Imaging, and Targeting. ( 27428386 )
2016
20
Dosimetric study for cervix carcinoma treatment using intensity modulated radiation therapy (IMRT) compensation based on 3D intracavitary brachytherapy technique. ( 27504132 )
2016
21
Pulsed-dose-rate vs. high-dose-rate intracavitary radiotherapy for locally advanced carcinoma of cervix: A prospective randomized study. ( 26996595 )
2016
22
Concurrent Cisplatin-Based Chemoradiation in Squamous Cell Carcinoma of Cervix. ( 27097702 )
2016
23
Clinicopathological Significance of Vimentin and Cytokeratin Protein in the Genesis of Squamous Cell Carcinoma of Cervix. ( 27190522 )
2016
24
Basaloid squamous cell carcinoma of cervix showing neuroendocrine differentiation. ( 26148627 )
2015
25
Evaluation of outcome and prognostic factors in 739 patients with uterine cervix carcinoma: a single institution experience. ( 26034391 )
2015
26
Systematic gene microarray analysis of the lncRNA expression profiles in human uterine cervix carcinoma. ( 26054679 )
2015
27
Adenoid cystic carcinoma of cervix: two cases report and review of the literature. ( 26090035 )
2015
28
Metastatic lobular carcinoma of breast mimics primary cervix carcinoma: two case reports and a review of the literature. ( 26435744 )
2015
29
The dosimetric impact of different photon beam energy on RapidArc radiotherapy planning for cervix carcinoma. ( 26865756 )
2015
30
Small cell neuroendocrine carcinoma of cervix and leiomyoma between the vagina and rectum. ( 25058833 )
2015
31
A Rare Case of Metastasis of Small Cell Carcinoma of Cervix to Breast. ( 29147420 )
2015
32
The association of GSTM1 and GSTT1 polymorphisms with squamous cell carcinoma of cervix in Pakistan. ( 25663492 )
2015
33
Characterization of Toll-like receptor transcriptome in squamous cell carcinoma of cervix: A case-control study. ( 26024767 )
2015
34
Clear cell carcinoma of cervix in a postmenopausal woman: A case report. ( 26167060 )
2015
35
An Audit of 204 Histopathology Reports Over Three Years of Carcinoma of Cervix: Experience from a Tertiary Referral Centre. ( 26320429 )
2015
36
Evaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy With Cobalt 60 in Carcinoma of Cervix. ( 26478798 )
2015
37
Invasive squamous cell carcinoma of cervix showing horizontal endometrial spread with extension and involvement of the myometrium: A case report. ( 26960456 )
2015
38
Adenoid cystic carcinoma of cervix in younger women: report of two new cases. ( 25722772 )
2014
39
Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. ( 24666257 )
2014
40
Synthetic racemates of abyssinone I and II induces apoptosis through mitochondrial pathway in human cervix carcinoma cells. ( 25019692 )
2014
41
Cervix carcinoma and incidental finding of medullary thyroid carcinoma by 18F-FDG PET/CT--clinical case. ( 25088110 )
2014
42
Human papilloma virus 16/18 genotypes in patients with squamous cell carcinoma of cervix in northeast Iran. ( 25538369 )
2014
43
Pre-treatment haemoglobin and peripheral blood lymphocyte count as independent predictors of outcome in carcinoma of cervix. ( 24439272 )
2014
44
Peptidyl-prolyl isomerase Pin1-mediated abrogation of APC-β-catenin interaction in squamous cell carcinoma of cervix. ( 24715170 )
2014
45
Significance of the plasma lipid profile in cases of carcinoma of cervix: a tertiary hospital based study. ( 24870793 )
2014
46
Concurrent chemoradiation for carcinoma of cervix: what lies beyond? ( 25022369 )
2014
47
Concurrent chemo-irradiation with weekly cisplatin and paclitaxel in the treatment of locally advanced squamous cell carcinoma of cervix: a phase II study. ( 25022387 )
2014
48
Continuous low-dose oral chemotherapy in recurrent and persistent carcinoma of cervix following chemoradiation: a comparative study between prolonged oral cyclophosphamide and oral Etoposide. ( 25191008 )
2014
49
Clear Cell Carcinoma of Cervix in a 60- year-old Woman: A Case Report. ( 25302238 )
2014
50
Abdominal scar recurrence of squamous cell carcinoma of cervix following simple hysterectomy. ( 25404838 )
2014

Variations for Cervix Carcinoma

ClinVar genetic disease variations for Cervix Carcinoma:

6 (show all 20)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.747G> T (p.Arg249Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs28934571 GRCh37 Chromosome 17, 7577534: 7577534
2 TP53 NM_000546.5(TP53): c.747G> T (p.Arg249Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs28934571 GRCh38 Chromosome 17, 7674216: 7674216
3 FGFR3 NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28931614 GRCh37 Chromosome 4, 1806119: 1806119
4 FGFR3 NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28931614 GRCh38 Chromosome 4, 1804392: 1804392
5 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
6 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 GRCh38 Chromosome 4, 1801837: 1801837
7 FGFR3 NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys) single nucleotide variant Pathogenic rs28933068 GRCh37 Chromosome 4, 1807371: 1807371
8 FGFR3 NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys) single nucleotide variant Pathogenic rs28933068 GRCh38 Chromosome 4, 1805644: 1805644
9 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
10 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh38 Chromosome 4, 1801841: 1801841
11 FGFR3 NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg) single nucleotide variant Pathogenic rs4647924 GRCh37 Chromosome 4, 1803571: 1803571
12 FGFR3 NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg) single nucleotide variant Pathogenic rs4647924 GRCh38 Chromosome 4, 1801844: 1801844
13 FGFR3 NM_000142.4(FGFR3): c.1949A> C (p.Lys650Thr) single nucleotide variant Pathogenic rs121913105 GRCh37 Chromosome 4, 1807890: 1807890
14 FGFR3 NM_000142.4(FGFR3): c.1949A> C (p.Lys650Thr) single nucleotide variant Pathogenic rs121913105 GRCh38 Chromosome 4, 1806163: 1806163
15 FGFR3 NM_000142.4(FGFR3): c.1993G> T (p.Ala665Ser) single nucleotide variant Uncertain significance rs764892330 GRCh37 Chromosome 4, 1808017: 1808017
16 FGFR3 NM_000142.4(FGFR3): c.1993G> T (p.Ala665Ser) single nucleotide variant Uncertain significance rs764892330 GRCh38 Chromosome 4, 1806290: 1806290
17 FGFR3 NM_000142.4(FGFR3): c.2153A> G (p.Asn718Ser) single nucleotide variant Uncertain significance rs139773438 GRCh37 Chromosome 4, 1808395: 1808395
18 FGFR3 NM_000142.4(FGFR3): c.2153A> G (p.Asn718Ser) single nucleotide variant Uncertain significance rs139773438 GRCh38 Chromosome 4, 1806668: 1806668
19 FGFR3 NM_000142.4(FGFR3): c.200G> A (p.Gly67Asp) single nucleotide variant Uncertain significance rs369232922 GRCh37 Chromosome 4, 1801071: 1801071
20 FGFR3 NM_000142.4(FGFR3): c.200G> A (p.Gly67Asp) single nucleotide variant Uncertain significance rs369232922 GRCh38 Chromosome 4, 1799344: 1799344

Expression for Cervix Carcinoma

Search GEO for disease gene expression data for Cervix Carcinoma.

Pathways for Cervix Carcinoma

GO Terms for Cervix Carcinoma

Biological processes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.83 CDKN2A CDKN3 INSM1 NBN TP53
2 response to drug GO:0042493 9.71 ABCB1 ABCC1 FOXO3 STAT3
3 negative regulation of cell proliferation GO:0008285 9.55 CDKN2A CDKN3 INSM1 STAT3 TP53
4 regulation of JNK cascade GO:0046328 9.46 MAPK8IP1 MAPK8IP2
5 replicative senescence GO:0090399 9.37 CDKN2A TP53
6 regulation of mitochondrial membrane permeability GO:0046902 9.32 STAT3 TP53
7 cell cycle arrest GO:0007050 9.26 CDKN2A CDKN3 NBN TP53
8 xenobiotic transport GO:0042908 8.96 ABCC1
9 DNA damage response, signal transduction by p53 class mediator GO:0030330 8.8 FOXO3 NBN TP53

Molecular functions related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.54 CDC27 STAT3 TP53
2 chromatin DNA binding GO:0031490 9.5 FOXO3 INSM1 STAT3
3 transcription factor binding GO:0008134 9.35 CDKN2A FOXO3 NBN STAT3 TP53
4 MAP-kinase scaffold activity GO:0005078 9.26 MAPK8IP1 MAPK8IP2
5 protein kinase binding GO:0019901 9.17 CDKN2A DUSP3 FOXO3 MAPK8IP1 MAPK8IP2 STAT3
6 xenobiotic transmembrane transporting ATPase activity GO:0008559 8.85 ABCC1

Sources for Cervix Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....